// Company Overview //
| Stock Name | 榮昌生物製藥(煙台)股份有限公司 - B - H 股 |
|---|---|
| Stock Code | 09995 |
| Company Full Name | 榮昌生物製藥(煙台)股份有限公司 - B - H 股 |
| Industry | 醫療保健 |
| Principal Activities | 主要從事生物制藥業務，專注於自身免疫、腫瘤及眼科疾病。 |
| Listing Date | 2020-11-09 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | No data |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國山東省自由貿易試驗區煙臺片區煙臺開發區北京中路58號 |
| Business Address (Hong Kong) | No data |
| Place of Incorporation | No data |
| Listing Method | No data |
| Listing Board | Main Board |
| Website | http://www.remegen.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
// Offering Information //
| Prospectus Date | 2020-10-28 |
|---|---|
| Offer Price | HK$ 52.10 / shares |
| Total Funds Raised | HK$ 1,595,041,500 |
// Valuation & Financials //
| Market Cap (at Offer Price) | HK$ 0 |
|---|
// First Day Performance
| First Day Close | Loading... |
|---|---|
| First Day Open | HK$ 60.6 |
| First Day Change | 33.97% |
| First Day Volume | 35719000.0 |
| First Day Turnover | 2297640000.0 |
// Price Chart //
Loading...
// Use of Proceeds
| Use of Proceeds | 1、約50.0%，或243.65百萬美元（1,888.29百萬港元），將主要用于候選藥物的臨床開發及商業化； 2、約25.0%，或121.82百萬美元（944.14百萬港元）將用于撥付建設新生產設施以擴大商業生產產能； 3、約15.0%，或73.09百萬美元（566.49百萬港元）將用于償還榮昌制藥借款； 4、約10.0%，或48.73百萬美元（377.66百萬港元）將用作一般企業及營運資金用途。 |
|---|
// Underwriting Syndicate //
联席保荐人 (3)
摩根士丹利亚洲有限公司
华泰金融控股（香港）有限公司
摩根大通证券(远东)有限公司
整体协调人 (4)
摩根士丹利亚洲有限公司
华泰金融控股（香港）有限公司
J.P. Morgan Securities (Asia Pacific) Limited
瑞银证券香港有限公司
联席账簿管理人 (8)
摩根士丹利亚洲有限公司
华泰金融控股（香港）有限公司
J.P. Morgan Securities (Asia Pacific) Limited
瑞银证券香港有限公司
中银国际亚洲有限公司
交银国际证券有限公司
海通国际证券有限公司
中泰国际证券有限公司
联席牵头经办人 (8)
摩根士丹利亚洲有限公司
华泰金融控股（香港）有限公司
J.P. Morgan Securities (Asia Pacific) Limited
瑞银证券香港有限公司
中银国际亚洲有限公司
交银国际证券有限公司
海通国际证券有限公司
中泰国际证券有限公司
// Cornerstone Investors //
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | BlackRock Funds | 154,997,500 HKD | — | 3.89% | — | 6 months | 2021-05-09 |
| 2 | Cherry Tomatoes International Limited | 38,736,350 HKD | — | 0.97% | — | 6 months | 2021-05-09 |
| 3 | Cormorant Asset Management, LP | 77,498,750 HKD | — | 1.94% | — | 6 months | 2021-05-09 |
| 4 | CPE Greater China Enterprises Growth Fund | 46,499,250 HKD | — | 1.17% | — | 6 months | 2021-05-09 |
| 5 | Fidelity International | 294,495,250 HKD | — | 7.39% | — | 6 months | 2021-05-09 |
| 6 | GIC Private Limited | 77,498,750 HKD | — | 1.94% | — | 6 months | 2021-05-09 |
| 7 | Hillhouse Funds | 77,498,750 HKD | — | 1.94% | — | 6 months | 2021-05-09 |
| 8 | Hudson Bay Master Fund LTD | 77,498,750 HKD | — | 1.94% | — | 6 months | 2021-05-09 |
| 9 | Janchor Partners Pan-Asian Master Fund | 92,998,500 HKD | — | 2.33% | — | 6 months | 2021-05-09 |
| 10 | Lake Bleu Prime Healthcare Master Fund Limited | 154,997,500 HKD | — | 3.89% | — | 6 months | 2021-05-09 |
| 11 | LAV Amber Limited | 154,997,500 HKD | — | 3.89% | — | 6 months | 2021-05-09 |
| 12 | Matthews Asia Funds | 77,498,750 HKD | — | 1.94% | — | 6 months | 2021-05-09 |
| 13 | Octagon Investments Master Fund LP | 61,999,000 HKD | — | 1.55% | — | 6 months | 2021-05-09 |
| 14 | OrbiMed Funds | 116,235,100 HKD | — | 2.92% | — | 6 months | 2021-05-09 |
| 15 | Vivo Funds | 77,498,750 HKD | — | 1.94% | — | 6 months | 2021-05-09 |
| 16 | 加皇环球资产管理(亚洲)有限公司 | 54,236,100 HKD | — | 1.36% | — | 6 months | 2021-05-09 |
| 17 | 新华资本管理有限公司 | 38,736,350 HKD | — | 0.97% | — | 6 months | 2021-05-09 |
| 18 | 易方达基金管理有限公司 | 42,617,800 HKD | — | 1.07% | — | 6 months | 2021-05-09 |
| 19 | 中国生物制药有限公司 | 46,499,250 HKD | — | 1.17% | — | 6 months | 2021-05-09 |
// Directors & Management //
| Chairman | 王威東 |
|---|---|
| Company Secretary | 譚栢如 |
No director data available.
// Major Shareholders //
| Major Shareholders & Holdings | 王威東及關連人士(41.36%);國家開發投資集團有限公司(5.51%) |
|---|
